Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Deals

Wuhan Weike Medical Technology Secures Series C Funding to Boost Cardiovascular Innovation

Fineline Cube Dec 21, 2024

Wuhan Weike Medical Technology Co., Ltd., known as “Weike Medical,” has officially announced the successful...

Company Deals

Sumitomo Pharma Expands Collaboration with Shanghai Pharmaceuticals for Prescription Drug Co-Marketing

Fineline Cube Dec 20, 2024

Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) has announced an expanded Contract Sales Organization (CSO)...

Company Medical Device

Boston Scientific’s Next-Gen IVUS System AVVIGO+ Approved by China’s NMPA for Coronary Disease Use

Fineline Cube Dec 20, 2024

US-based Boston Scientific Corporation (NYSE: BSX) has announced that China’s National Medical Products Administration (NMPA)...

Company Deals

Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic

Fineline Cube Dec 20, 2024

US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with...

Company Drug

Roche’s Prasinezumab Shows Promise in Phase IIb PADOVA Study for Early-Stage Parkinson’s Disease

Fineline Cube Dec 20, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has published results from the Phase IIb PADOVA study...

Company Deals

Hainan Boao Lecheng and Sanofi Partner with Paris-Saclay Cancer Cluster for Advanced Cancer Treatments

Fineline Cube Dec 20, 2024

The Hainan Boao Lecheng International Medical Tourism Pilot Zone, in collaboration with France’s major Sanofi’s...

Company Drug

Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China

Fineline Cube Dec 20, 2024

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its...

Company Deals

WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio

Fineline Cube Dec 20, 2024

China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic...

Company Deals

MGI Tech Co., Ltd Partners with Sabin Group to Enhance Genetic Sequencing in Brazil

Fineline Cube Dec 20, 2024

China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has entered into a strategic...

Company Deals

Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB

Fineline Cube Dec 20, 2024

Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo...

Company Deals

BioArctic AB Secures Global Rights to PyroGlu-Aβ Antibody Program in BMS Deal

Fineline Cube Dec 20, 2024

Sweden-based BioArctic AB (OTCMKTS: BRCTF) has announced a significant licensing agreement with US pharmaceutical giant...

Company Deals

Fangzhou Inc. Partners with BMS to Innovate Digital Medicine Platform

Fineline Cube Dec 20, 2024

China-based Internet healthcare solutions provider Fangzhou Inc. (HKG: 6086) has entered into a partnership with...

Company Digital

Sanofi and Corxel Pharmaceuticals Partner for Aficamten in Greater China Rights

Fineline Cube Dec 20, 2024

Global healthcare leader Sanofi (NASDAQ: SNY) and China-based Corxel Pharmaceuticals (CORXEL), formerly known as Ji...

Company Deals

HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies

Fineline Cube Dec 20, 2024

China-based in vitro diagnostic (IVD) reagents specialist HOB Biotech Group Corp., Ltd (SHA: 688656) has...

Company Drug

Joincare Pharmaceutical’s JKN2403 Gains NMPA Approval for COPD Clinical Trials

Fineline Cube Dec 20, 2024

China-based Jo2006incare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) is set to advance its Category...

Company Drug

Sino Biopharmaceutical Ltd. Files for Benmelstobart and Anlotinib Combination Therapy in ASPS Treatment

Fineline Cube Dec 20, 2024

China-based Sino Biopharmaceutical Ltd (HKG: 1177) is poised to make another indication approval filing with...

Company Deals

HighTide Therapeutics and SSY Group Ltd Join Forces to Tackle Metabolic and Aging Diseases

Fineline Cube Dec 20, 2024

China-based HighTide Therapeutics Inc. (HKG: 2511) has announced a strategic collaboration framework agreement with compatriot...

Company Drug

AIM Vaccine Co., Ltd Receives NMPA Clearance for Innovative Cell-Based Influenza Vaccine

Fineline Cube Dec 20, 2024

AIM Vaccine Co., Ltd (HKG: 6660), a China-based biopharmaceutical company, has announced that it has...

Company Deals

Henlius Biotech Expands Partnership with Palleon Pharmaceuticals for Autoimmune Disease Treatment

Fineline Cube Dec 20, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a leading biotechnology company based in China, has announced...

Company Drug

AIM Vaccine Co., Ltd Receives NMPA Approval for Second-Gen Tetanus Vaccine Clinical Trial

Fineline Cube Dec 20, 2024

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced that it has received clinical trial...

Posts pagination

1 … 236 237 238 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.